Resistance to cisplatin

Anti-Cancer Drug Design

Volumn 14, Issue 2, 1999, Pages 143-151

  Akiyama, Shin Ichi ^a   Chen, Zhe Sheng ^a   Sumizawa, Tomoyuki ^a   Furukawa, Tatsuhiko ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Cisplatin; cMOAT; GS X pump; Modulator; Resistance

Indexed keywords

CARRIER PROTEIN; CISPLATIN; DNA; GLUTATHIONE; METALLOTHIONEIN;

DNA REPAIR; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TRANSPORT; GENE EXPRESSION; HUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 0033046213     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Aebi S., Kurdi-Haidar B., Gordon R., Cenni B., Zheng H., Fink D., Christen R.D., Boland C.R., Koi M., Fishel R., Howell S.B. (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Research , 56, 3987.
2. Andrews P.A. (1994) Mechanisms of aquired resistance to cisplatin. In Anticancer Drug Resistance: Advances in Molecular and Clinical Research. Goldstein L.J., Ozols R.F. (eds), p. 217. Kluwer: Boston, MA.
3. Andrews P.A., Albright K.A. (1991) Role of membrane ion transport in cisplatin accumulation. In Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Howell S.B. (ed.), p. 151. Plenum Press: New York.
4. Andrews P.A., Murphy M.P., Howell S.B. (1985) Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Research, 45, 6250.
5. Andrews P.A., Murphy M.P., Howell S.B. (1987) Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemotherapy and Pharmacology, 19, 149.
6. Andrews P.A., Mann S.C., Howell S.B. (1988) cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Research, 48, 68.
7. +-adenosine triphosphatase in the accumulation of cis-dimminedichloroplatinum(II) in human ovarian carcinoma cells. Cancer Research, 51, 3677.
8. Anthoney D.A., McIlwrath A.J., Gallagher W.M., Edlin A.R.M., Brown R. (1996) Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Research, 56, 1374.
9. Asahina H., Kuraoka I., Shirakawa M., Morita E.H., Miura N., Miyamoto I., Ohtsuka E., Okada Y, Tanaka K. (1994) The XPA protein is a zinc metalloprotein with an ability to recognize various kinds of DNA damage. Mutation Research, 315, 229.
10. Bakka A., Endresen L., Johnsen A.B., Edminson P.D., Rugstad H.E. (1981) Resistance against cis-dichlorodiammineplatinum in cultured cells with a high content of metallothionein. Toxicology and Applied Pharmacology, 61, 215.
11. Benz C.C., Scott G.K., Sarup J.C. Johnson R.M., Tripathy D., Coronado E., Shepard H.M., Osborne C.K. (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Research and Treatment, 24, 85.
12. Bergerat J-.P., Drewinko B., Corry P., Barlogie B., Ho D.H. (1981) Synergistic lethal effect of cis-dichlorodiammineplatinum and I-β-D-arabinofuranosylcytosine. Cancer Research, 41, 25.
13. Bramson J., Panasci L.C. (1993) Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damaging agents. Cancer Research, 53, 3237.
14. Bungo M., Fujiwara Y, Kasahara K., Nakagoe K., Ohe Y., Sasaki Y, Irino S., Saijo N. (1990) Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Research, 50, 2549.
15. Chapman R.S., Whetton A.D., Chresta C.M., Dive G. (1995) Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase. Molecular Pharmacology, 48, 334.
16. Chen Z.S., Mutoh M., Sumizawa T., Furukawa T., Haraguchi M., Tani A., Saijo N., Kondo T., Akiyama S. (1998) An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells. Experimental Cell Research, 240, 312.
17. Chuman Y., Chen Z.S., Sumizawa T., Furukawa T., Haraguchi M., Takebayashi Y., Niwa K., Yamada K., Aikou T., Akiyama S. (1996) Characterization of the ATP-dependent LTC4 transporter in cisplatin-resistant human KB cell. Biochemical and Biophysical Research Communications, 226, 158.
18. Cole S.P.C., Sparls K.E., Fraser K., Loe D.W., Grant C.E., Wilson G.M., Deely R.G. (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Research, 54, 5902.
19. Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J.J., Reed E. (1994) Messenger RNA levels of XPAG and ERCCI in ovarian cancer tissue correlate with response to platinum-based chemotherapy. Journal of Clinical Investigation, 94, 703.
20. Dempke W.C., Shellard S.A., Fichtinger-Schepman A.M., Hill B.T. (1991) Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumor cell lines in vitro. Carcinogenesis, 12, 525.
21. Dixit M., Yang J.L., Poirier M.C., Price J.O., Andrews P.A., Arteaga C.L. (1997) Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. Journal of the National Cancer Institute, 89, 365.
22. Dornish J.M., Pettersen E.O., Oftebro R. (1989) Modifying effect of cinnamaldehyde and cinnamaldehyde on cell inactivation and cellular uptake of cis-diamminedichloroplatinum(II) in human NHIK 3025 cells. Cancer Research, 49, 3917.
23. Drummond J.T., Anthoney A., Brown R., Modrich P. (1996) Cisplatin and Adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line. Journal of Biological Chemistry, 271, 19645.
24. Eastman A., Schulte N. (1988) Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry, 27, 4730.
25. Eastman A. (1991) Mechanism of resistance to cisplatin. In Molecular and Clinical Advance in Anticancer Drug Resistance. Ozols R.F. (ed.), p. 233. Kluwer: Boston, MA.
26. Fink D., Nebel S., Aebi S., Zheng H., Cenni B., Nehme A., Christen R.D., Howell S.B. (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Research, 56, 4881.
27. Fink D., Aebi S., Howell S.B. (1998) The role of DNA mismatch repair in drug resistance. Clinical Cancer Research, 4, 1.
28. Fraval H.N.A., Rawlings C.J., Roberts J.J. (1978) Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrororrus luteus. Mutation Research, 51, 121.
29. Fujii R., Mutoh M., Niwa K. Yamada K., Aikou T., Nakagawa M., Kuwano M., Akiyama S. (1994a) An active efflux system for cisplatin in cisplatin-resistant human KB cells. Japanese Journal of Cancer Research, 85, 426.
30. Fujii R., Mutoh M., Sumizawa T., Chen Z.S., Yoshimura A., Akiyama S. (1994b) Adenosine triphosphate-dependent transport of leukotriene C4 by membrane vesicles prepared from cisplatinuim-resistant human epidermoid carcinoma tumor cells. Journal of the National Cancer Institute, 86, 1781.
31. Fujiwara T., Grimm E.A., Mukhopadhyay T., Zhang W.W., Owen-Schaub L.B., Roth J.A. (1994) Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Research, 54, 2287.
32. Funato T., Yoshida E., Jiao L., Tone T., Kashani-Sabet M., Scanlon K.J. (1992) The utility of an anti-fos ribozyme in reversing cisplatin resistace in human carcinomas. Advances in Enzyme Regulation, 32, 195.
33. Gately D.P., Howell S.B. (1993) Cellular accumulation on the anticancer agent cisplatin: a review. British Journal of Cancer, 61, 1171.
34. Goto S., Yoshida K., Morikawa T., Urata Y., Suzuki K., Kondo T. (1995) Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. Cancer Research, 55, 4297.
35. Gottesman M.M., Pastan I. (1988) The multidrug transporter, a double-edged sword. Journal of Biological Chemistry, 263, 12163.
36. Hamilton T.C., Winker M.A., Louie K.G., Batist G., Behrens B.C., Tsuruo T., Grotzinger K.R., McKoy W.M., Young R.C., Ozols R.F. (1985) Augmentation of adriamycin, melphalan, and sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochemical Pharmacology, 34, 2583.
37. Hamilton T.C., Lai G.M., Rothenberg M.L., Fojo A.T., Young R.C., Ozols R.F. (1989) Mechanisms of resistance to cisplatin and alkylating agents. In Drug Resistance in Cancer Therapy. Ozols R.F. (ed.), p. 151. Kluwer: Boston, MA.
38. Haneda H., Katabami M., Miyamoto H., Isobe H., Shimizu T., Ishiguro A., Moriuti T., Takasaki Y., Kawakami Y. (1991) The relationship of the proliferating cell nuclear antigen protein to cis-diamminedichloroplatinum(II) resistance of a murine leukemia cell line P338/CDDP. Oncology, 48, 234.
39. 2 cell cycle checkpoint. Cancer Research, 55, 3721.
40. Hettinga J.V.E., Konings A.W., Kampinga H.H. (1997) Reduction of cellular cisplatin resistance by hyperthermia - a review. International Journal of Hyperthermia, 13, 439.
41. Hromas R.A., Andrews P.A., Murphy M.P., Burns C.P. (1987a) Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Letters, 34, 9.
42. Hromas R.A., North J.A., Burns C.P. (1987b) Decreased cisplatin uptake by resistant L1210 leukemia cells. Cancer Letters, 36, 197.
43. Ishikawa T. (1992) The ATP-dependent glutathione S-conjugate export pump. Trends in Biological Science, 17, 463.
44. Ishikawa T., Ali-Osman F. (1993) Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Journal of Biological Chemistry, 268, 20116.
45. Ishikawa T., Bao J.J., Yamane Y., Akimaru K., Frindrich K., Wright C.D., Kuo M.T. (1996) Coordinated induction of MRP/GS-X pump and γ-glutamylcysteine synthetase by heavy metals in human leukemia cells. Journal of Biological Chemistry, 271, 14981,
46. Isonishi S., Hom D.K., Thiebaut F.B., Mann S.C., Andrews PA., Basu A., Lazo IS., Eastman A., Howell S.B. (1991) Expression of the c-Ha-Ras oncogene induces resistance to cisplatin. Cancer Research, 51, 5903.
47. Jekunen A.P., Shalinsky D.R., Hom D.K., Albright K.D., Heath D., Howell S.B. (1993) Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane by digitonin in vitro. Biochemical Pharmacology, 45, 2079.
48. Kasahara K., Fujiwara Y., Nishio K., Ohmori T., Sugimoto Y., Komiya K., Matsuda T., Saijo N. (1991) Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Research, 51, 3237.
49. Kasahara K., Fujimura M., Bando T., Shibata K., Shirasaki H., Matsuda T. (1996) Modulation of sensitivity to cis-diamminedichioroplatinum(II) by thromboxane A2 receptor antagonists in non-small-cell lung cancer cell lines. British Journal of Cancer, 74, 1553.
50. Katabami M., Fujita H., Haneda H., Akita H., Kazumaki N., Miyamoto H., Kawakami Y. (1992) Reduced drug accumulation in a newly established human lung squamous-carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Biochemical Pharmacology, 44, 394.
51. Kelland L.R., Mistry P., Abel G., Loh S.Y., O'Neill C.F., Murrer B.A., Harrap K.R. (1992) Mechanism-related circumvention of acquired cis-diamminedichloroplatinum (II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum IV dicarboxylates. Cancer Research, 52, 3857.
52. Kelley S.L., Basu A., Teicher B.A., Hacker M.P., Hamer D.H., Lazo J.S. (1988) Overexpression of metallothionein confers resistance to anticancer drugs. Science, 241, 1813.
53. Kern D.H., Morgan C.R. (1988) In vitro pharmacodynamics of I-β-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Research, 48, 117.
54. Koike K., Kawabe T., Tanaka T., Toh S., Uchiumi T., Wada M., Akiyama S., Ono M., Kuwano M. (1997) A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Research, 57, 5475.
55. Kondo Y., Woo E.S., Michalska A.E., Choo K.H.A., Lazo J.S. (1995) Metallothionein null cells have increased sensitivity to anticancer drugs. Cancer Research, 55, 2021.
56. Kool M., de Haas M., Scheffer G.L., Scheper R.J., van Eijk M.J.T., Juijn J.A., Baas F., Borst P. (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5 homologues of the multidrug resistance-associated protein gene (MRP1) in human cancer cell lines. Cancer Research, 51, 3537.
57. Kraker A.J., Moore C.W. (1988) cis-Diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Research, 48, 9.
58. Lai G.M., Ozols R.F., Smyth J.F., Young R.C., Hamilton T.C. (1988) Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochemical Pharmacology, 37, 4597.
59. Lai G.M., Ozols R.F., Young R.C., Hamilton T.C. (1989) Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. Journal of the National Cancer Institute, 81, 535.
60. Loehrer P.J., Einhorn L.H. (1984) Cisplatin. Annals of Internal Medicine, 100, 704.
61. Loh S.Y., Mistry P., Kelland L.R., Abel G., Harrap K.R. (1992) Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum(II) and (VI) ammine/amine complexes. British Journal of Cancer, 66, 1109.
62. Mann S.C., Andrews P.A., Howell S.B. (1990) Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemotherapy and Pharmacology, 25, 236.
63. Mann S.C., Andrews P.A., Howell S.B. (1991) Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. International Journal of Cancer, 48, 866.
64. Masuda H., Ozols R.F., Lai G.M., Fojo A., Rothenberg M., Hamilton T.C. (1988) Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Research, 48, 5713.
65. Masuda H., Tanaka T., Matsuda H., Kusaba I. (1990) Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistance to cis-diamminedichloroplatinum(II). Cancer Research, 50, 1863.
66. Meijer C., Mulder N.H., de Vries E.G.E. (1990) The role of detoxifying systems in resistance of tumor cells to cisplatin and Adriamycin. Cancer Treatment Reviews, 17, 389.
67. Meijer C., Mulder N.H., Timmer-Bosscha H., Sluiter W.J., de Vries E.G.E. (1992) Relationship of cellular glutathione to the cytotoxicity and the resistance of seven platinum compounds. Cancer Research, 52, 6885.
68. L can confer a multidrug resistance phenotype. Blood, 86, 1903.
69. Mistry P., Kelland L.R., Abel G., Sidhar S., Harrap K.R. (1991) The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. British Journal of Cancer, 64, 215.
70. Miyashita T., Reed J.C. (1993) Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81, 151.
71. Morikage T., Bungo M., Inomata M., Yoshida M., Ohmori T., Fujiwara Y., Nishio K., Saijo N. (1991) Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line. Japanese Journal of Cancer Research, 82, 747.
72. Morikage T., Ohmori T., Nishio K., Fujiwara Y., Takeda Y., Saijo N. (1993) Modulation of cisplatin senstivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines. Cancer Research, 53, 3302.
73. Murphy M.P., Andrews P.A., Howell S.B. (1985) Metallothionein mediated cisplatin and melphalan resistance in human ovarian carcinoma. Proceedings of the American Association for Cancer Research, 26, 334.
74. L and caspase-3-like proteases. Proceedings of the National Academy of Sciences, USA, 95, 5724.
75. 2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and deficient cells exposed to cisplatin. Cancer Research, 57, 3253.
76. Ohga T., Koike K., Ono M., Makino Y., Itagaki Y., Tanimoto M., Kuwano M., Kohno K. (1996) Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C and ultraviolet light. Cancer Research, 56, 4224.
77. Pattanaik A., Bachowski G., Laib J., Lemkuil D., Shaw C.F. 3rd, Petering D.H., Hitchcock A., Saryan L. (1992) Properties of the reaction of cis-diamminedichloroplatinum(II) with metallothionein. Journal of Biological Chemistry, 267, 16121.
78. Payne A., Chu G. (1994) Xeroderma pigmentosum group E binding factor recognizes a broad spectrum of DNA damage. Mutation Research, 310, 89.
79. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., Veerman G., Kuiper C.M., Braakhuis B.J.M. (1996) Interactions between cisplatin and gemcitabine in vitro and in vivo. Seminars in Oncology, 22(suppl. 11), 72.
80. Richon V.M., Schulte N., Eastman A. (1987) Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Research, 47, 2056.
81. Scanlon K.J., Kashani-Sabet M., Miyachi H., Sowers L.C., Rossi J. (1998) Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. Anticancer Research, 9, 1301.
82. Sheibani N., Jennerwein M.M., Eastman A. (1989) DNA repair in cells sensitive and resistance to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. Biochemistry, 28, 3120.
83. Shen D.W., Pastan I., Gottesman M.M. (1998) Cross-resistance to mothotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Research, 58, 268.
84. L can differentially block chemotherapy-induced cell death. Blood, 90, 1208.
85. Sklar M.D. (1988) Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Research, 48, 793.
86. Sorenson C.M., Eastman A. (1988) Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Research, 48, 6703.
87. Swinnen L.J., Barnes D.M., Fisher S.G., Albain K.S., Fisher R.I., Erickson L.C. (1989) I-β-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking. Cancer Research, 49, 1383.
88. Timmer-Bosscha H., Mulder N.H., de Vries E.G.E. (1992) Modulation of cis-diamminedichloplatinum(II) resistance: a review. British Journal of Cancer, 66, 227.
89. Ueda K., Suzuki H., Akiyama S., Sugiyama Y. (1999) Japanese Journal of Cancer Research, 90, 439.
90. Vadi H., Drewinko B. (1986) Kinetics and mechanism of the I-β-D-arabinofuranosylcytosine potentiation of cis-diamminedichloroplatinum(II) cytotoxicity. Cancer Research, 46, 1105.
91. Vaisman A., Varchenko M., Umar A., Kunkel T.A., Risinger J.I., Barrett J.C., Hamilton T.C., Chaney S.G. (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Research, 58, 3579.
92. Yamazaki H., Schneider E., Myers C.E, Sinha B.K. (1994) Oncogene overexpression and de novo drug-resistance in human prostate cancer cells. Biochimica et Biophysica Acta, 1226, 89.
93. Yang L.-Y., Li L., Keating M.J., Plunkett W. (1995) Arabinosyl-2-fluoracine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Molecular Pharmacology, 47, 1072.
94. Yao K.-S., Godwin A.K., Johnson S.W., Ozols R.F., O'Dwyer P.J., Hamilton T.C. (1995) Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Research, 55, 4367.
95. Yokomizo A., Ono M., Nanri H., Makino Y., Ohga T., Wada M., Okamoto T., Yodoi J., Kuwano M., Kohno K. (1995) Cellular levels of thioredoxin associated with drub sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Research, 55, 4293.
96. Zamble D. B., Lippard S.J. (1995) Cisplatin and DNA repair in cancer chemotherapy. Trends in Biological Science, 20, 435.
97. Zelazowski A.J., Garvey J.S., Hoeschele J.D. (1984) In vitro binding of platinum to metallothionein. Archives of Biochemistry and Biophysics, 229, 246.